Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is an American life science and clinical diagnostics manufacturer headquartered in Hercules, California. Founded in 1952, the company reported 2025 revenue of USD 2,583 million with approximately 7,400 employees and ten manufacturing and research facilities across the United States, France, Singapore and China.

Company Overview

Bio-Rad occupies a particular position in laboratory instrumentation: it makes the tools that scientists use at the bench, before and alongside the expensive analytical platforms that attract most industry attention. Protein electrophoresis, gel imaging, blotting membranes, polymerase chain reaction reagents and chromatography media are unglamorous products, but they are consumed continuously by almost every molecular biology laboratory in the world, which gives Bio-Rad a revenue base that is less dependent on capital equipment cycles than that of its larger competitors.

The company's 2025 revenue of 2,583 million dollars was split between a life science segment contributing 980 million dollars and a clinical diagnostics segment contributing 1,603 million dollars. That balance is unusual in the industry and materially reduces volatility, because diagnostic testing demand is driven by patient volumes rather than by research budgets.

Core Strengths

The first strength is workflow entrenchment. A laboratory that has standardised its western blotting protocol on Bio-Rad gels and transfer membranes must continue buying the same consumables to keep its results comparable over time, and validation requirements in regulated laboratories make switching expensive. Electrophoresis and imaging are not high-margin products individually, but they generate predictable repeat revenue across a very large installed base.

The second strength is droplet digital PCR, where Bio-Rad is one of only two significant global suppliers. Digital PCR partitions a sample into thousands of individual reactions and counts the positive ones, giving absolute quantification without a standard curve, which makes it the technique of choice for detecting rare mutations in oncology samples, measuring gene copy number and validating next-generation sequencing results. The acquisition of Stilla Technologies strengthened this position and added a complementary platform.

The third strength is the diagnostics business. Blood typing, immunohematology, autoimmune testing and diabetes monitoring generate revenue from hospital laboratories that is insulated from research funding cycles, and the segment is larger than the life science business. The fourth is geographic manufacturing: facilities in France, Singapore and China allow Bio-Rad to serve regional markets from within them, which matters increasingly as tariffs reshape instrument supply chains. The fifth is the company's substantial holding in Sartorius AG, whose market value gives Bio-Rad a balance sheet far stronger than its revenue would suggest.

Challenges Ahead

The 2025 results expose the company's main vulnerability. Gross margin fell from 53.7 percent to 51.9 percent, operating margin came in below management's expectations, and the chief executive characterised the year as challenging, citing geopolitical uncertainty and continued pressure on academic research funding. Those two factors affect Bio-Rad more than most competitors because a large share of its life science revenue comes from academic and government laboratories, the customer category most directly exposed to shifts in public research budgets.

The scale question is also unresolved. At 2,583 million dollars of revenue, Bio-Rad is roughly a third the size of Waters and a sixth of Agilent, which limits both its research budget and its ability to absorb tariff and currency shocks. Management entered 2026 with a commitment to improving overall performance, but the company has not articulated a strategy for moving up-market into the high-value analytical platforms where its competitors earn their margins.

VerityRank Score of 83/100, reflecting entrenched bench-level positions and a large diagnostics business, constrained by margin compression and exposure to academic funding.